SeattleNTC

Dear Washington Colleagues: I have some excellent news! Over the past few weeks, we have started two new clinical trials! I am posting each separately due to LinkedIn word limits. We are actively recruiting for a study on methylone (similar to MDMA) for Post-Traumatic Stress Disorder (PTSD)! To refer patients: - PTSD study: Transcend@seattlentc.com Transcend IMPACT-2: An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD Major Points: -      exciting small Phase 2 trial, happening at 7-8 locations -      methylone is somewhat similar to MDMA but likely to have milder effects -      participants receive weekly methylone for 4 weeks (4 dosing days total) -      dosing is under supervision of a therapist -      randomized to one of three doses (low, mid, or high); no placebo condition Key Inclusion / Exclusion Criteria: -      severe PTSD with 6+ months duration -      tried at least one treatment for PTSD, either meds or therapy -      PTSD is the most severe or prominent psychiatric disorder; comorbidities such as depression must be milder -      some medications are not allowed during the study For more information on IMPACT-2 study of methylone for PTSD, please see: ClinicalTrials.gov ID NCT06215261 https://lnkd.in/gfkvChsi

Washington Physicians: House Bill 1430, which requires ARNP/PO and MD/DO reimbursement "parity" for psychiatry and primary care -- the bill that declares 11 years of my life as wasted time -- has now passed out of committee. Note that they decided this bill was too expensive for government programs, but this would require private insurance to enforce this equivalence of pay. This is exactly the opposite of fairness, the opposite of "parity," and undermines the very people they say they value because there is a shortage. Testimony on this bill was cut short on Tuesday and most of the Committee had left at that point. My colleague Dr. Kat Jong came from the islands, stayed overnight in Seattle, just to testify; we drove together for 2 hours to show up for the hearing. Neither she nor I, there in person, were called to testify, while multiple ARNPs in favor of the bill were called to testify remotely from home. Now is the time to freak out. Please help. Please email the Governor about this bill, and email your Washington State Senate representatives. ALL physicians should take this action, because if the legislature is willing to say now that my/psychiatrists' 8 years+ of education has no more value than an 18-24 month mostly online graduate program, what are they going to say about you next? Thank you in advance for your action!

SAVE THE DATE! We’re thrilled to announce that the 2025 ISEN Annual Meeting will take place on May 18, 2025, in vibrant Los Angeles, California! As part of this incredible event, don’t miss the ISEN ECT In-Person Course, happening on May 17, 2025. This comprehensive course, led by world-renowned experts, is designed to enhance your knowledge and skills in electroconvulsive therapy (ECT) and keep you at the forefront of clinical practice. What to Expect: ✨ Cutting-edge research presentations ✨ Inspiring keynote speakers ✨ Networking opportunities with global experts ✨ Workshops and hands-on training for ECT practitioners ✨ Insights into the future of brain stimulation therapies Whether you're a seasoned practitioner or new to the field, this conference and course are your opportunities to connect, collaborate, and advance the practice of ECT and neurostimulation. Mark your calendar and stay tuned for updates on registration, program details, and special events! #ISEN25 #BrainStimulation #ECT #Neurostimulation #MedicalConference #Research #Education #Service #PatientCare #Psychiatry

Hello Psychiatric and Mental Health clinicians! I wanted to put a few reminders out there in case any of the following is of interest to your patients: - We continue to be the only clinic in the region offering the SAINT TMS protocol for depression, through a program called Open Label Optimization. SAINT TMS involves an fMRI to find an individualized treatment target, followed by an intensive 5 days of treatment. - The psilocybin trial, COMPASS, is still enrolling! Please consider referring your patients who have depression and have failed 2-4 antidepressants in the current episode (since the last time they had 2 months without significant depression). - Our PTSD trial is starting! We are a part of a multisite trial on a new method of customizing TMS, using EEG. Please consider referring your patients who have PTSD. Although the first part of the study is a randomized trial (RCT), all patients in the sham/placebo group will have the opportunity to receive the active treatment after the RCT is done. - The VNS trial, RECOVER, is still enrolling! Please consider referring your highly treatment-resistant bipolar patients who are depressed. It's exciting keeping up with all of you on Linked In, and the amazing work you're doing!

Key Clinical Takeaways from CTMSS London 2024 For Addictions Part 1 “Innovative Addiction Treatment Exploring the Global Landscape of Transcranial Magnetic Stimulation (TMS) in Substance Use Disorders” Speaker: Colleen Hanlon, PhD Addictions result from dysfunction in brain networks This leads to Impairment in response inhibition and salience attribution There are two key regulatory approvals for TMS for Addictions Europe- CE TMS for Psychostimulants (Cocaine) Target: DLPFC with Figure of Eight Coil Stimulation Protocol: 100% of MT, 10HZ 4 sec on, 15 sec off, 40 trains, 2400 pulses One session a day for five days, then 2x a day once a week for 11 weeks US- FDA TMS for Nicotine Use Disorder Target: DACC with H4 Coil Stimulation Protocol: 120% of MT, 10HZ, 3 sec on, 15 sec off, 60 trains, 1800 pulses One session a day for 15 days, then one weekly for three weeks. Can we change cue reactivity and impulsivity by targeting the mPCC? This should result in drinking days in Alcohol Use Disorder. Two studies suggest we can! Harel et al. 2021 Target: mPCC with H-7 coil Stimulation Protocol: 10HZ, 3000 pulses per session for 15 sessions Cue Prime: Yes McCalley et al. 2022 Target: mPCC with DB-60 Stimulation Protocol: 3600 Pulses, cTBS Cue Prime: Yes References https://lnkd.in/gngHKYRm https://lnkd.in/gB9bc32m https://lnkd.in/gbM7gkXf #CTMSS2024 #empathyminded #AddictionTreatment #TMS #SubstanceUseDisorder